Palisade Bio (PALI) Price & Analysis

Compare

599 Followers

PALI Stock Chart & Stats

$2.14

-$0.36(-15.79%)

At close: Jan 08 4:00 PM EST

$2.14

-$0.36(-15.79%)

Day’s Range― - ―

52-Week Range$0.53 - $3.30

Previous CloseN/A

Volume307.14K

Average Volume (3M)12.47M

Market Cap

$318.87M

Enterprise Value-$1.81M

Total Cash (Recent Filing)$5.23M

Total Debt (Recent Filing)$211.00K

Price to Earnings (P/E)―

Beta0.04

Next Earnings

Nov 17, 2025

EPS Estimate

-0.27

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.58

Shares Outstanding149,003,200

10 Day Avg. Volume14,066,214

30 Day Avg. Volume12,469,954

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)0.31

Price to Sales (P/S)0.00

P/FCF Ratio-0.19

Enterprise Value/Market Cap>-0.01

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit1.81K

Enterprise Value/Ebitda0.16

Forecast

1Y Price Target

$8.00

Price Target Upside273.83% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe Phase 1b study included ulcerative colitis patients and achieved 100% clinical response with patients showing histological improvements across multiple parameters, and well-tolerated.

Financial PositionRecent financing supports trials for PALI-2108 and potential approval, indicating a stronger financial position.

Market OpportunityThere are no FDA-approved therapeutics for fibrostenotic Crohn's disease, making it a large market opportunity with minimal competition.

Bears Say

Palisade Bio News

Palisade Bio price target raised to $8 from $2 at Maxim

Maxim raised the firm’s price target on Palisade Bio (PALI) to $8 from $2 and keeps a Buy...

5d ago

PALI

Palisade Bio appoints Sharon Skare as global head, clinical operations

Palisade Bio (PALI) announced the appointment of Sharon Skare as Vice President, Global Head of Clinical Operations. Skare...

19d ago

PALI

Palisade Bio announces first patients dosed in Phase 1b study of PALI-2108

Palisade Bio (PALI) announced that the first patients have been dosed in its Phase 1b clinical study evaluating...

27d ago

PALI

Palisade Bio Terminates Phantom Unit Plan

Palisade Bio ( ($PALI) ) has provided an announcement. On September 4, 2025, Palisade Bio, Inc. approved a...

25d ago

PALI

Palisade Bio Approves Reverse Stock Split Amendment

Palisade Bio ( ($PALI) ) just unveiled an update. On October 17, 2025, Palisade Bio, Inc. held its...

27d ago

PALI

Palisade Bio Regains Nasdaq Compliance on Stock Price

Palisade Bio ( ($PALI) ) has shared an announcement. On October 15, 2025, Palisade Bio, Inc. announced it...

1M ago

PALI

Palisade Bio granted Canadian patent covering PALI-2108 composition

Palisade Bio (PALI) announced that the Canadian Intellectual Property Office has granted patent number 3,174,137 titled, “Gut Microbiota...

1M ago

PALI

Palisade Bio Cancels Stockholder Meeting Due to Quorum

Palisade Bio ( ($PALI) ) has provided an update. On October 9, 2025, Palisade Bio announced the cancellation...

1M ago

PALI

Palisade Bio prices 171.4M shares at 70c in upsized underwritten public offering

Palisade Bio (PALI) announced the pricing of an underwritten public offering of 171,440,559 shares of its common stock...

2M ago

PALI

Palisade Bio files to sell 147.1M shares of common stock

Ladenburg Thalmann is acting as manager. Published first on TheFly – the ultimate source for real-time, market-moving breaking...

2M ago

PALI

Palisade Bio Adjourns Stockholder Meeting Due to Quorum

Palisade Bio ( ($PALI) ) has issued an update. On September 26, 2025, Palisade Bio, Inc. attempted to...

2M ago

PALI

Palisade Bio Reschedules Stockholder Meeting Due to Quorum Issue

Palisade Bio ( ($PALI) ) just unveiled an announcement. On September 18, 2025, Palisade Bio, Inc. adjourned a...

2M ago

PALI

Optimistic Buy Rating for Palisade Bio: Promising Clinical Trials and Strategic Market Expansion

In a report released yesterday, Naz Rahman from Maxim Group reiterated a Buy rating on Palisade Bio, with...

2M ago

PALI

Palisade Bio reports results from PALI-2108 Phase 1b data

Palisade Bio (PALI) announced new data from its ongoing clinical program evaluating PALI-2108, a first-in-class, ileocolonic-targeted PDE4 B/D...

2M ago

PALI

PALI FAQ

What was Palisade Bio’s price range in the past 12 months?

Palisade Bio lowest stock price was $0.53 and its highest was $3.30 in the past 12 months.

What is Palisade Bio’s market cap?

Palisade Bio’s market cap is $318.87M.

When is Palisade Bio’s upcoming earnings report date?

Palisade Bio’s upcoming earnings report date is Nov 17, 2025 which is tomorrow.

How were Palisade Bio’s earnings last quarter?

Palisade Bio released its earnings results on Aug 19, 2025. The company reported -$0.581 earnings per share for the quarter, beating the consensus estimate of -$0.594 by $0.013.

Is Palisade Bio overvalued?

According to Wall Street analysts Palisade Bio’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Palisade Bio pay dividends?

Palisade Bio does not currently pay dividends.

What is Palisade Bio’s EPS estimate?

Palisade Bio’s EPS estimate is -0.27.

How many shares outstanding does Palisade Bio have?

Palisade Bio has 149,003,200 shares outstanding.

What happened to Palisade Bio’s price movement after its last earnings report?

Palisade Bio reported an EPS of -$0.581 in its last earnings report, beating expectations of -$0.594. Following the earnings report the stock price went down -2.5%.

Which hedge fund is a major shareholder of Palisade Bio?

Currently, no hedge funds are holding shares in PALI

Palisade Bio Stock Smart Score

Neutral

Fundamentals

Return on Equity

-228.64%

Trailing 12-Months

Asset Growth

-48.20%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Palisade Bio

Palisade Bio (PALI) is a biopharmaceutical company focused on developing therapeutics that protect the integrity of the intestinal barrier. The company's core product candidates are designed to address unmet medical needs in the fields of gastrointestinal health, specifically targeting conditions such as inflammatory bowel disease (IBD) and postoperative digestive complications. Utilizing its proprietary technology, Palisade Bio aims to create innovative treatments that improve patient outcomes and quality of life.

Palisade Bio (PALI) Earnings & Revenues

Historic Earnings Reports

PALI Stock 12 Month Forecast

Average Price Target

$8.00

▲(273.83% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","9":"$9","-1":"-$1","1.5":"$1.5","6.5":"$6.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.5,4,6.5,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.07,2.526153846153846,2.982307692307692,3.4384615384615382,3.8946153846153844,4.350769230769231,4.806923076923077,5.263076923076923,5.719230769230769,6.1753846153846155,6.631538461538462,7.087692307692308,7.543846153846154,{"y":8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.07,2.526153846153846,2.982307692307692,3.4384615384615382,3.8946153846153844,4.350769230769231,4.806923076923077,5.263076923076923,5.719230769230769,6.1753846153846155,6.631538461538462,7.087692307692308,7.543846153846154,{"y":8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.07,2.526153846153846,2.982307692307692,3.4384615384615382,3.8946153846153844,4.350769230769231,4.806923076923077,5.263076923076923,5.719230769230769,6.1753846153846155,6.631538461538462,7.087692307692308,7.543846153846154,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.08,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.65,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.53,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.45,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.77,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.4,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.65,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.83,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.67,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.78,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.01,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.66,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.07,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >